Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | GOT1 | P17174 | 9/20 | 0.50 |
| ▸ | MGLL | Q99685 | 2/20 | 0.49 |
| ▸ | CCR3 | P51677 | 1/20 | 0.47 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27554175 | 0.99 | GAA (0.56) | GAAMAPTMAPK14RECQLGOT1 | |
| SCHEMBL6097059 | 0.83 | MAPK14 (0.57) | GAAMAPTMAPK14RECQLGOT1 | |
| Hydrochloric Acid SCHEMBL27576776 | 0.82 | MAPK14 (0.56) | GAAMAPTMAPK14RECQLGOT1 | |
| SCHEMBL6098281 | 0.82 | GAA (0.44) | GAAMAPTRECQLAVPR1A | |
| SCHEMBL5277129 | 0.82 | MAPK14 (0.60) | GAAMAPTMAPK14RECQLGOT1 | |
| SCHEMBL5925678 | 0.81 | MAPK14 (0.51) | GAAMAPTMAPK14RECQLGOT1 | |
| SCHEMBL6095064 | 0.77 | GHSR (0.57) | GAAMAPTMAPK14RECQLMGLL | |
| SCHEMBL6098930 | 0.76 | MAPK14 (0.56) | GAAMAPTMAPK14RECQLMGLL | |
| Hydrochloric Acid SCHEMBL27574062 | 0.76 | GHSR (0.56) | GAAMAPTMAPK14RECQLMGLL | |
| SCHEMBL6095813 | 0.76 | MAPK14 (0.57) | GAAMAPTMAPK14RECQLGOT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7084143-B2 | N-(indolecarbonyl) piperazine derivatives | MERCK PATENT GMBH (DE) | 2006-08-01 | — | — | US | claimed |
| US-6838461-B1 | N-(indolcarbonyl-)piperazine derivatives | MERCK PATENT GMBH (DE) | 2005-01-04 | — | — | US | claimed |
| US-20050096330-A1 | N-(indolecarbonyl) piperazine derivatives | BOETTCHER HENNING (DE) | 2005-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096330-A1 | N-(indolecarbonyl) piperazine derivatives | HTR2A, HTR2B, HTR2C | GAA 2544/4885MAPT 1280/4885MAPK14 4409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.